Nearly 80% of the approved human therapeutic antibodies are produced by Chinese
Hamster Ovary (CHO) cells. To achieve better cell growth and high-yield recombinant …

Today's biomanufacturing processes are still operated based on experience, and thus can
hardly cope with increasing bioprocess complexity. Recently, there is a growing interest in …

Recombinant antibodies are rapidly developing therapeutic agents; approximately 40 novel
antibody molecules enter clinical trials each year, most of which are produced from Chinese …

With omics data being generated at an unprecedented rate, genome-scale modelling has
become pivotal in its organisation and analysis. However, machine learning methods have …

The control of nutrient availability is critical to large‐scale manufacturing of biotherapeutics.
However, the quantification of proteinogenic amino acids is time‐consuming and thus is …

In order to meet the rising demand for biologics and become competitive on the developing
biosimilar market, there is a need for process intensification of biomanufacturing processes …

Recent noteworthy advances in developing high‐performing microbial and mammalian
strains have enabled the sustainable production of bio‐economically valuable substances …

The production of monoclonal antibodies (mAbs) using Chinese Hamster Ovary (CHO) cells
has revolutionized the treatment of numerous diseases, solidifying their position as a …

Genome-scale metabolic models comprehensively describe an organism's metabolism and
can be tailored using omics data to model condition-specific physiology. The quality of …

Flux balance analysis (FBA) is currently the standard method to compute metabolic fluxes in
genome-scale networks. Several FBA extensions employing diverse objective functions …